| __timestamp | Eli Lilly and Company | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 1244910 |
| Thursday, January 1, 2015 | 6533000000 | 5029636 |
| Friday, January 1, 2016 | 6452000000 | 4846776 |
| Sunday, January 1, 2017 | 6588100000 | 5329003 |
| Monday, January 1, 2018 | 5975100000 | 7121000 |
| Tuesday, January 1, 2019 | 6213800000 | 9128000 |
| Wednesday, January 1, 2020 | 6121200000 | 10731000 |
| Friday, January 1, 2021 | 6431600000 | 10701000 |
| Saturday, January 1, 2022 | 6440400000 | 16121000 |
| Sunday, January 1, 2023 | 6941200000 | 37021000 |
| Monday, January 1, 2024 | 8593800000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. Eli Lilly and Company, a stalwart in the industry, showcases a consistent SG&A (Selling, General, and Administrative) expense trend from 2014 to 2023. Their expenses hover around $6.4 billion annually, peaking at $6.9 billion in 2023, reflecting a strategic investment in growth and market presence.
In contrast, Viking Therapeutics, Inc., a burgeoning biotech firm, demonstrates a different trajectory. Starting with a modest $1.2 million in 2014, their SG&A expenses surged to $37 million by 2023, marking a staggering 2,900% increase. This growth underscores their aggressive expansion and development strategy.
This analysis highlights the diverse strategies of established versus emerging companies in managing operational costs, offering insights into their market positioning and future potential.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and PTC Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Amgen Inc. vs Viking Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared